Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered · not yet curatedtopotecan
Educational only, not medical advice. OncoForge makes no claim that Topotecan treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.
Simple Summary
Auto-discovered from 1 recent study; not yet curated.
Research
Where the evidence is
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
CancerHuman evidenceMechanismSafetyTrial
Advanced Or Metastatic High Grade Epithelial Ovarian Cancer—1—1
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
The panel suggested primary cytoreductive surgery as the initial approach when complete resection is feasible.
Neoadjuvant chemotherapy followed by interval surgery was suggested when complete cytoreduction is unlikely or the patient has poor functional status/comorbidities.
Bevacizumab was suggested with platinum-based chemotherapy for high-risk disease, with maintenance only if it was part of first-line therapy.
PARP inhibitors (olaparib, niraparib, rucaparib) were suggested as maintenance in selected BRCA/HRD-defined groups.
For platinum-resistant relapse, sequential non-platinum single-agent chemotherapy and best supportive care for poor performance status were suggested.
Limitations: This is a consensus statement/practice guideline, not an original comparative trial.; No new efficacy or safety data are reported in the abstract.; Recommendations are based on literature review and expert agreement, so they are subject to guideline-selection and expert-opinion bias.; The abstract does not provide patient-level outcomes, follow-up, or effect estimates.; Several recommendations are conditional/suggested rather than based on direct evidence from this paper..
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
What changed recently
The latest additions to Topotecan's evidence base, and anything that's been retracted.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
No human studies yet · No numeric effect sizes reported · Based on a single study.
Dose: as studied, not a recommendation
These are doses as studied or reported, never a recommendation. The right amount of Topotecan depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.
Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.